Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder
The lack of adequate treatment for many patients with opioid use disorder (OUD) has led to high medical costs ($90B in 2020). An analysis of the cost-effectiveness (cost-utility) of reSET-O, the first and only FDA-approved prescription digital therapeutic (PDT) for the treatment of OUD, is needed to...
Saved in:
| Main Authors: | Fulton F. Velez, Daniel C. Malone |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2021.1966187 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effective interventions to prevent prescription drug misuse: a systematic review
by: L. Yesenia Rodríguez-Tanta, et al.
Published: (2025-03-01) -
Therapeutic Journey and Economic Burden of Patients with Myasthenia Gravis in Italy: Results of a Real-World Analysis
by: Valentina Perrone, et al.
Published: (2025-01-01) -
Overcoming barriers to traditional care delivery and pharmacy challenges: a qualitative study of buprenorphine, telehealth, and a digital therapeutic for opioid use disorder
by: Laura B. Monico, et al.
Published: (2025-02-01) -
Healthcare utilization trends among patients with opioid use disorder in U.S. Hospitals: an analysis of length of stay, total charges, and costs, 2005–2020
by: Fares Qeadan, et al.
Published: (2025-07-01) -
A spatiotemporal analysis of opioid prescriptions in Indiana from 2015 to 2019
by: Paula A. Jaimes-Buitron, et al.
Published: (2025-08-01)